Skip to main content
NASDAQ:TXMD

TherapeuticsMD Competitors

$1.06
+0.04 (+3.92 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.02
$1.08
50-Day Range
$1.02
$1.42
52-Week Range
$1.00
$2.75
Volume8.84 million shs
Average Volume13.13 million shs
Market Capitalization$416.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19

Competitors

TherapeuticsMD (NASDAQ:TXMD) Vs. KURA, AMRX, AVIR, HRTX, SUPN, and SAVA

Should you be buying TXMD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to TherapeuticsMD, including Kura Oncology (KURA), Amneal Pharmaceuticals (AMRX), Atea Pharmaceuticals (AVIR), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), and Cassava Sciences (SAVA).

TherapeuticsMD (NASDAQ:TXMD) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares TherapeuticsMD and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Kura OncologyN/A-30.96%-28.02%

Volatility & Risk

TherapeuticsMD has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Valuation and Earnings

This table compares TherapeuticsMD and Kura Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Kura OncologyN/AN/A$-63,140,000.00($1.51)-16.56

Kura Oncology has lower revenue, but higher earnings than TherapeuticsMD. Kura Oncology is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for TherapeuticsMD and Kura Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Kura Oncology011002.91

TherapeuticsMD currently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Kura Oncology has a consensus target price of $39.4545, suggesting a potential upside of 57.82%. Given TherapeuticsMD's higher possible upside, equities research analysts plainly believe TherapeuticsMD is more favorable than Kura Oncology.

Insider and Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Comparatively, 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TherapeuticsMD beats Kura Oncology on 7 of the 13 factors compared between the two stocks.

TherapeuticsMD (NASDAQ:TXMD) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares TherapeuticsMD and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Amneal Pharmaceuticals3.30%42.02%3.82%

Volatility & Risk

TherapeuticsMD has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares TherapeuticsMD and Amneal Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Amneal Pharmaceuticals$1.63 billion1.01$-361,920,000.00$0.2720.30

TherapeuticsMD has higher earnings, but lower revenue than Amneal Pharmaceuticals. TherapeuticsMD is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for TherapeuticsMD and Amneal Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Amneal Pharmaceuticals01402.80

TherapeuticsMD currently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Amneal Pharmaceuticals has a consensus target price of $7.40, suggesting a potential upside of 35.04%. Given TherapeuticsMD's higher possible upside, equities research analysts plainly believe TherapeuticsMD is more favorable than Amneal Pharmaceuticals.

Insider and Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats TherapeuticsMD on 9 of the 14 factors compared between the two stocks.

TherapeuticsMD (NASDAQ:TXMD) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares TherapeuticsMD and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Atea PharmaceuticalsN/AN/AN/A

Insider and Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares TherapeuticsMD and Atea Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than TherapeuticsMD.

Analyst Recommendations

This is a summary of recent recommendations for TherapeuticsMD and Atea Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Atea Pharmaceuticals00403.00

TherapeuticsMD currently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Atea Pharmaceuticals has a consensus target price of $69.3333, suggesting a potential upside of 260.74%. Given TherapeuticsMD's higher possible upside, equities research analysts plainly believe TherapeuticsMD is more favorable than Atea Pharmaceuticals.

TherapeuticsMD (NASDAQ:TXMD) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

TherapeuticsMD has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Profitability

This table compares TherapeuticsMD and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Heron Therapeutics-216.18%-65.06%-49.14%

Insider & Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 99.0% of Heron Therapeutics shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Comparatively, 12.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares TherapeuticsMD and Heron Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Heron Therapeutics$145.97 million10.84$-204,750,000.00($2.50)-6.21

TherapeuticsMD has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for TherapeuticsMD and Heron Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Heron Therapeutics01402.80

TherapeuticsMD presently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Heron Therapeutics has a consensus target price of $27.50, suggesting a potential upside of 77.02%. Given TherapeuticsMD's higher possible upside, research analysts clearly believe TherapeuticsMD is more favorable than Heron Therapeutics.

TherapeuticsMD (NASDAQ:TXMD) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Volatility & Risk

TherapeuticsMD has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Profitability

This table compares TherapeuticsMD and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Supernus Pharmaceuticals27.09%20.02%9.67%

Insider & Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares TherapeuticsMD and Supernus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Supernus Pharmaceuticals$392.76 million4.03$113.06 million$2.1014.20

Supernus Pharmaceuticals has higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for TherapeuticsMD and Supernus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Supernus Pharmaceuticals00203.00

TherapeuticsMD presently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Supernus Pharmaceuticals has a consensus target price of $37.50, suggesting a potential upside of 25.71%. Given TherapeuticsMD's higher possible upside, research analysts clearly believe TherapeuticsMD is more favorable than Supernus Pharmaceuticals.

Summary

Supernus Pharmaceuticals beats TherapeuticsMD on 9 of the 14 factors compared between the two stocks.

TherapeuticsMD (NASDAQ:TXMD) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Risk and Volatility

TherapeuticsMD has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares TherapeuticsMD and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TherapeuticsMD-327.98%N/A-78.47%
Cassava SciencesN/A-22.01%-20.85%

Earnings and Valuation

This table compares TherapeuticsMD and Cassava Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$49.65 million8.39$-176,150,000.00($0.68)-1.56
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-139.93

Cassava Sciences has lower revenue, but higher earnings than TherapeuticsMD. Cassava Sciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.6% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are owned by institutional investors. 13.8% of TherapeuticsMD shares are owned by insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for TherapeuticsMD and Cassava Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TherapeuticsMD11302.40
Cassava Sciences00503.00

TherapeuticsMD presently has a consensus target price of $5.0667, suggesting a potential upside of 377.99%. Cassava Sciences has a consensus target price of $46.00, suggesting a potential upside of 21.76%. Given TherapeuticsMD's higher possible upside, equities analysts clearly believe TherapeuticsMD is more favorable than Cassava Sciences.

Summary

TherapeuticsMD beats Cassava Sciences on 7 of the 13 factors compared between the two stocks.


TherapeuticsMD Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kura Oncology logo
KURA
Kura Oncology
1.6$25.00+1.0%$1.66 billionN/A-15.34Analyst Downgrade
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.48+2.9%$1.64 billion$1.63 billion13.37
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.22+2.7%$1.59 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$15.54+12.1%$1.58 billion$145.97 million-6.29Earnings Announcement
Analyst Upgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.83+1.3%$1.58 billion$392.76 million12.38
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$37.78+0.8%$1.51 billionN/A-157.42
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$26.10+3.9%$1.48 billionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
uniQure logo
QURE
uniQure
1.7$31.70+0.9%$1.46 billion$7.28 million-8.41Earnings Announcement
Analyst Revision
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.09+2.4%$1.45 billionN/A0.00Earnings Announcement
News Coverage
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$20.89+3.8%$1.44 billion$2.34 million-8.85
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$32.75+4.4%$1.43 billionN/A-11.03
Kronos Bio logo
KRON
Kronos Bio
1.7$25.37+0.2%$1.42 billionN/A0.00Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$10.96+3.0%$1.40 billion$320,000.00-7.46Gap Up
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$39.15+13.2%$1.39 billionN/A0.00Earnings Announcement
Insider Selling
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.79+6.7%$1.31 billionN/A0.00Earnings Announcement
Analyst Report
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.6$29.03+2.4%$1.30 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.1$12.75+3.0%$1.29 billion$261.02 million6.51
Endo International logo
ENDP
Endo International
1.5$5.53+1.8%$1.29 billion$2.91 billion-8.13Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$25.55+6.7%$1.28 billionN/A-2.77High Trading Volume
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.40+2.5%$1.28 billion$82.27 million-15.61Earnings Announcement
Analyst Revision
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.00+1.0%$1.27 billion$230,000.00-13.49
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.16+1.5%$1.27 billion$6.20 million-12.79Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$26.62+3.6%$1.23 billion$29.54 million-7.06Analyst Report
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$33.38+7.3%$1.23 billionN/A-18.54Earnings Announcement
Analyst Revision
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.72+0.8%$1.22 billion$73.41 million-3.96Analyst Report
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.28+1.6%$1.17 billion$59.70 million-192.80
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.19+3.3%$1.15 billionN/A0.00Earnings Announcement
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$18.90+2.6%$1.14 billion$175.34 million-11.12
Omeros logo
OMER
Omeros
1.4$18.33+2.6%$1.14 billion$111.81 million-7.70Earnings Announcement
Analyst Downgrade
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$14.97+2.7%$1.14 billion$4.23 million-8.36
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.24+2.5%$1.11 billion$4.23 million-15.73
Shattuck Labs logo
STTK
Shattuck Labs
1.5$26.16+6.1%$1.10 billionN/A0.00Earnings Announcement
Insider Selling
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$27.01+3.6%$1.09 billion$800.40 million25.48Analyst Report
News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$46.32+4.8%$1.08 billionN/A0.00Analyst Downgrade
High Trading Volume
Analyst Revision
Zogenix logo
ZGNX
Zogenix
2.0$19.24+3.4%$1.07 billion$3.65 million-2.02Insider Buying
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$33.99+3.2%$1.06 billionN/A-2.43Analyst Upgrade
Insider Selling
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.18+0.2%$1.06 billionN/A-6.97
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$29.25+6.5%$1.05 billion$57.05 million0.00Earnings Announcement
Analyst Revision
News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.41+3.3%$1.02 billion$227.19 million51.14Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.30+0.8%$1.02 billion$122.47 million-27.64
MannKind logo
MNKD
MannKind
1.4$4.03+0.2%$1.00 billion$63.04 million-19.19Earnings Announcement
Analyst Report
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$14.35+1.1%$990.88 million$42.12 million-10.63Earnings Announcement
Analyst Revision
Humanigen logo
HGEN
Humanigen
1.7$16.73+1.7%$981.33 millionN/A0.00Earnings Announcement
Upcoming Earnings
Analyst Report
OLMA
Olema Pharmaceuticals
1.6$24.07+1.7%$966.89 millionN/A0.00Earnings Announcement
Lockup Expiration
Analyst Revision
News Coverage
Gap Up
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.73+0.8%$965.56 millionN/A-12.78Earnings Announcement
News Coverage
Radius Health logo
RDUS
Radius Health
1.1$20.15+3.7%$951.95 million$173.32 million-8.26Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$13.83+6.5%$943.65 millionN/A-5.84
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$19.56+2.5%$931.74 million$322.36 million139.71Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$19.20+4.7%$919.97 millionN/A-7.08Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$27.15+3.7%$917.13 millionN/A-25.14High Trading Volume
Analyst Revision
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.